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Abstract
Background:  Alkaline phosphatase (ALP) is an important enzyme mainly derived from the liver,
bones and in lesser amounts from intestines, placenta, kidneys and leukocytes. An increase in ALP
levels in the serum is frequently associated with a variety of diseases. This study was done in order
to determine the diseases associated with a high ALP level among Thai adult hospitalized patients.
Method:  A review was made of medical records of inpatients with high ALP level above 1000 IU/
L in King Chulalongkorn Memorial Hospital, Thailand from January 1999 to December 1999.
Excluded were cases of (a) patients who have bone involvements with malignancies, (b) pediatric
patients younger than 15 years old and c) HIV-seropositive patients.
Results:  A total of 181 hospitalized patients with eligible medical records were identified (96
males and 85 females, mean age 49.4 ± 16.1 years). Their ALP levels ranging from 1,001 to 3,067
IU/L, these patients were divided into four groups.
Conclusion:  High serum ALP levels in hospitalized patients were commonly found in three major
groups having obstructive biliary diseases, infiltrative liver disease and sepsis. The study results
were in accordance with previous reports in developed countries. Nonetheless,
cholangiocarcionoma and some tropical diseases unique to our setting were also detected in these
cases. where there was a marked elevation of serum ALP.
Background
Alkaline phosphatase (ALP; EC 3.1.3.1) comprises a
group of enzymes that catalyze the hydrolysis of phos-
phate esters in an alkaline environment, generating an
organic radical and inorganic phosphate.[1] Like other
enzymes, this enzyme has many isoenzymes. In healthy
adults, this enzyme is mainly derived from the liver,
bones and in lesser amounts from intestines, placenta,
kidneys and leukocytes.[2]
An increase in serum ALP levels is frequently associated
with a variety of diseases. Such disorders as extrahepatic
bile obstruction, intrahepatic cholestasis, infiltrative liv-
er disease and hepatitis are mentioned. Unfortunately,
the elevation of ALP less than three times the normal lev-
el is considered non specific and insufficient to provide a
definite diagnosis. [3]
Markedly elevated serum ALP, hyperalkalinephos-
phatasemia, is seen predominantly with more specific
disorders, including, malignant biliary obstruction, pri-
mary biliary cirrhosis, primary sclerosing cholangitis,
hepatic lymphoma and sarcoidosis.[4] On the other
hand, according to a recent study [5], sepsis and malig-
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peralkalinephosphatasemia, whereas diffuse liver
metastasis, as well as a number of benign disorders, are
relatively less common causes of hyperalkalinephos-
phatasemia.
In order to determine the diseases associated with mark-
edly elevated serum ALP among Thai adult hospitalized
patients, a review was made of medical records of indi-
viduals in whom an ALP level was equal to or greater
than 1,000 IU/L during a one-year period in a Thai terti-
ary hospital.
Materials and methods
This study was performed as a retrospective study. A ret-
rospective case review was made on hospitalized patients
who had an ALP level equal to or greater than 1,000 IU/
L (Boerhinger Manheim, normal 98 – 279 IU/L) at the
Department of Laboratory Medicine, King Chulalongko-
rn Memorial Hospital, Bangkok, Thailand.
This study focused on a one-year period, from January
1999 to December 1999. Exclusion was made in cases of
(a) patients who have bone involvements with malignan-
cies, (b) pediatric patients younger than 15 years old and
c) HIV seropostive patients. The review of the patients'
medical records during this period identified 181 cases
with a conclusive diagnosis for further analysis. The data
from the discharge summary of these patients were then
recorded including their age and sex, as well as the final
diagnosis.
Descriptive statistics were used in analyzing the patient
characteristics and laboratory parameters for each
group. In addition, unpaired Student's T test was used to
assess group differences when appropriate. Independ-
ence was tested by Chi square test. A statistical signifi-
cant difference was accepted as P value < 0.05. All the
statistical analyses in this study were made using SPSS
7.0 for Windows Program.
Results
During the one-year period, a total of 181 hospitalized
patients with serum ALP level over 1000 IU/L were iden-
tified. They were 102 male and 96 female patients with
ages ranging from 21 to 90 years old (mean age 49.4 ±
16.1 years). The ALP levels ranged from 1,001 to 3,067
IU/L.
The most common diagnosis in patients with high ALP in
our series was malignant biliary obstruction. This was
found in 58 patients, 48 of whom were cases with
cholangicocarcinoma (CCA). Of the remaining 10, three
were with pancreatic cancer, one with ampullary cancer,
one with metastatic cancer, and five with periampullary
cancer. The ALP levels ranged from 1,005 to 3,067 IU/L
(average 1,869.8 ± 325.3 IU/L). In addition, benign duct
obstruction from choledocholithiasis was found in an-
other 14 patients, six of which cases were complicated by
ascending cholangitis. The ALP level in this group
ranged from 1,001 to 2,864 IU/L (average 1,498.3 ±
541.2 IU/L). Comparing these two groups, the mean ALP
levels in the malignant biliary obstruction group was sig-
nificantly higher (P < 0.05).
The second common group of disorders associated with
high serum ALP levels was infiltrative liver disorders.
Among the 181 patients in the study, 23 had hepatoma
diagnosed based on histology and/or based on clinical
features combined with serum AFP levels above 400 IU/
ml. The ALP level in this group ranged from 1,030 to
2,534 IU/L (average 1,449.9 ± 356.2 IU/L). There were
also 26 cases with liver metastasis in which a variety of
primary cancers were identified, including ovary, colon,
stomach, esophagus, lung, and breast cancer. The ALP
levels in this group ranged from 1,207 to 3,004 IU/L (av-
erage 1,652.3 ± 233.6 IU/L). Interestingly, the mean ALP
level in patients in the metastatic cancer group was sig-
nificantly higher than that in the primary hepatoma
group (P < 0.05).
Then, high serum ALP above 1000 IU/L was also com-
mon in patients with sepsis. Our data revealed that there
were such 41 patients in whom the evidence of the biliary
obstruction or local abscess was not demonstrated by
imaging techniques. In this group, bacteria were among
the most frequently identified organisms (30 cases). In
addition, another two cases with fungal infections fol-
lowing systemic chemotherapy exhibited high serum
ALP levels. Of interest, a number of common tropical in-
fections in Thailand were also identified, including mel-
lioidosis(1 case), leptospirosis(1 case), scrup typhus (1
case) and typhoid fever(2 cases). Furthermore, there
were 4 patients with disseminated tuberculosis. In this
group of patients with sepsis, the ALP levels ranged from
1,010 to 2,944 IU/L (average 1,668.2 ± 498.4 IU/L).
Finally, there was this group of patients with high ALP
levels associated with miscellaneous diseases. The19 pa-
tients remaining from the three groups above had the
following various disorders: 1) Seven patients with he-
matological malignancies (4 cases with acute myelocytic
leukemia (AML) in blast crisis stage, 2 cases with chronic
myelocytic leukemia (CML) and 1 case with non-Hodg-
kin lymphoma, (ALP levels ranged from 1,015 to 2,987
IU/L, averaging 1,941.1 ± 532.4 IU/L); 2) six alcoholic
cirrhosis cases (ALP levels ranged from 1,002 to 2,741
IU/L, averaging 1,271.4 ± 746.4 IU/L); 3) two pyogenic
liver abcess (ALP levels ranged from 1,011 to 1,876 IU/L,
averaging 1,443.5 ± 432.5 IU/L); 4) four 4 severe preec-
BMC Family Practice 2001, 2:2 http://www.biomedcentral.com/1471-2296/2/2lampsia cases (ALP levels ranged from 1,476 to 2,132 IU/
L, averaging 1,624.0 ± 742.4 IU/L).
A summary of the disorders associated with hyperalka-
linephosphatasemia in patients with different ALP levels
is shown in Table 1. Meanwhile, in this restrospective
study of the patients' records, no significant correlation
between the level of ALP elevation and the group of dis-
orders was detected (Chi-square test, P > 0.05) (Table 1).
Discussion
Most data indicate that the elevation of serum ALP oc-
curs because of the accerelated de novo synthesis of the
enzyme and subsequent regurgitation into the serum.
[1,2] A number of diseases are related to the elevation of
serum ALP.
The study of the etiologies of high serum ALP can be use-
ful data in diagnosis. Sepsis-associated cholestasis is a
well-known condition, and increased ALP is a common
laboratory finding in the patients with intra- or extra-he-
patic cholestasis. [6,7] According to the study of Lee et al,
elevated ALP was common in patients who had liver ab-
cess with superimposed Klebsiella bacteraemia.[8]
In this study, the etiologies of high levels of ALP in 181
Thai adult patients were retrospectively examined. As a
specific population of hospitalized patients was particu-
larly for this study, the results may not apply to the gen-
eral outpatient population. Nonetheless, several findings
from this study should be noted.
Firstly, three major categories of diseases, namely, ob-
structive biliary diseases, infiltrative liver diseases and
sepsis, were identified as the three common disorders as-
sociated with serum ALP exceeding 1000 IU/L in our se-
ries. Unlike a similar previous study [5], high prevalence
of malignant biliary obstruction, accounting for approx-
imately 30 % of patients in the study, was identified.
This discordance probably reflected the high prevalence
of cholangiocarcinoma (CCA) in our studies. This result
also confirmed the previous data [9] that CCA is the most
common cause of hyperalkalinephosphatasemia among
the Thai cancerous cases. In fact, CCA is an important
cancer in Southeast Asia, especially in Thailand and La-
os. The highest incidence of CCA in this region corre-
sponds with the high incidence of a tropical parasite,
Opisthorchis viverini, among the local population. [10]
Secondly, concerning the patients with infiltrative liver
diseases, it was observed that the average serum ALP lev-
el in the metastasis group was statistically significant
higher than that in the primary hepatoma group.
Finally, some tropical diseases prevailing in Thailand
were also identified as exhibiting high serum ALP level,
including mellioidosis, leptospirosis, scrub typus and ty-
phoid fever. It has previously been suggested that the de-
velopment of liver dysfunction in these diseases could
indicate severity. [1,2]
Conclusion
Various disorders were associated with high serum ALP
levels in hospitalized patients. The three major underly-
ing etiologies in our series were a) obstructive biliary dis-
eases, b) infiltrative liver diseases and c) sepsis. Our
results were in accordance with previous studies in de-
veloped countries. However, two interesting findings
unique to our setting were identified. One was the high
prevalence of cholangiocarcinoma as cause ofhyperalka-
linephosphatasemia. The other was that several tropical
diseases were essential etiologies of marked elevation of
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